BidaskClub lowered shares of Prevail Therapeutics (NASDAQ:PRVL) from a buy rating to a hold rating in a research note published on Saturday morning, BidAskClub reports.

A number of other analysts also recently issued reports on the stock. Wedbush boosted their price objective on shares of Prevail Therapeutics from $19.00 to $22.00 and gave the company an outperform rating in a report on Tuesday, May 26th. Zacks Investment Research downgraded shares of Prevail Therapeutics from a strong-buy rating to a hold rating in a report on Thursday, May 28th. Citigroup initiated coverage on shares of Prevail Therapeutics in a report on Thursday, March 5th. They set a buy rating and a $24.00 price target for the company. Piper Sandler initiated coverage on shares of Prevail Therapeutics in a report on Thursday, April 9th. They set an overweight rating and a $20.00 price target for the company. Finally, ValuEngine raised shares of Prevail Therapeutics from a hold rating to a buy rating in a report on Thursday, April 2nd. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus price target of $20.00.

NASDAQ PRVL opened at $14.66 on Friday. The company has a quick ratio of 14.32, a current ratio of 14.32 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $498.98 million and a P/E ratio of -6.40. Prevail Therapeutics has a 12-month low of $7.41 and a 12-month high of $19.96. The firm has a 50-day moving average price of $16.39 and a two-hundred day moving average price of $15.76.

Prevail Therapeutics (NASDAQ:PRVL) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.50) by ($0.06). Equities analysts expect that Prevail Therapeutics will post -2.33 EPS for the current year.

A number of hedge funds have recently added to or reduced their stakes in PRVL. Legal & General Group Plc increased its position in Prevail Therapeutics by 50.1% during the 1st quarter. Legal & General Group Plc now owns 2,146 shares of the company’s stock worth $26,000 after purchasing an additional 716 shares in the last quarter. Fred Alger Management LLC acquired a new position in Prevail Therapeutics during the 4th quarter worth approximately $47,000. BNP Paribas Arbitrage SA increased its position in Prevail Therapeutics by 380.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 4,142 shares of the company’s stock worth $50,000 after purchasing an additional 3,279 shares in the last quarter. Victory Capital Management Inc. increased its position in Prevail Therapeutics by 162.0% during the 1st quarter. Victory Capital Management Inc. now owns 4,748 shares of the company’s stock worth $58,000 after purchasing an additional 2,936 shares in the last quarter. Finally, Deutsche Bank AG increased its position in Prevail Therapeutics by 95.8% during the 1st quarter. Deutsche Bank AG now owns 5,043 shares of the company’s stock worth $61,000 after purchasing an additional 2,468 shares in the last quarter. Institutional investors and hedge funds own 80.50% of the company’s stock.

Prevail Therapeutics Company Profile

Prevail Therapeutics Inc, a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The company's lead product candidate is PR001 for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease.

Read More: CBOE Russell 2000® Volatility Index

Analyst Recommendations for Prevail Therapeutics (NASDAQ:PRVL)

Receive News & Ratings for Prevail Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prevail Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.